Fortress Biotech vs Verrica Pharmaceuticals
FBIO and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FBIO and VRCA compare
Fortress Biotech and Verrica Pharmaceuticals are about the same size, with market caps of $73.9M and $67.2M.
Verrica Pharmaceuticals grew revenue faster over the last twelve months (106% versus 15.5% for Fortress Biotech).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −103% at Verrica Pharmaceuticals.
Fortress Biotech scores higher on the StockData Score (9 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FBIO | VRCA |
|---|---|---|
| Size and price | ||
| Market cap | $73.9M | $67.2M |
| Share price | $2.01 | $3.91 |
| Change, 1 year | −22.4% | 1.0% |
| Change, 5 years | −95.7% | −96.6% |
| Beta (5Y) | 1.38 | 1.09 |
| Employees | 78 | 76 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 2.2× |
| P/B | 0.5× (better) | 15.6× |
| Growth | ||
| Revenue growth (TTM) | 15.5% | 106% (better) |
| Revenue growth, 5Y average | 6.8% | – |
| Profitability | ||
| Gross margin | 65.6% | – |
| Operating margin | −42.9% (better) | −93.6% |
| Net margin | 163% (better) | −103% |
| Return on equity | 107% | – |
| Return on invested capital | −261% | – |
| Financial health | ||
| Debt / equity | 0.21 | – |
| Interest coverage | −3.0× (better) | −7.6× |
| Current ratio | 3.96 (better) | 1.45 |
| Altman Z-score | −1.75 (better) | −13.66 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.9% | 27.1% |
| Held by insiders | 31.6% | – |
| Insider net buying, 12 months | – | $211K |
Go deeper
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.